ProfileGDS5678 / 1449580_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 87% 97% 87% 88% 88% 90% 92% 81% 81% 87% 86% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6544487
GSM967853U87-EV human glioblastoma xenograft - Control 26.583786
GSM967854U87-EV human glioblastoma xenograft - Control 36.6388587
GSM967855U87-EV human glioblastoma xenograft - Control 49.7841397
GSM967856U87-EV human glioblastoma xenograft - Control 56.8076187
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.683688
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.725988
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2165890
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.6238892
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8419281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8408981
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8111687
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5727386
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9326882